By Diagnostics World Staff
December 11, 2025 | Illumina today announced an investment and collaboration into MyOme, a genomics and risk modeling company. The collaboration and investment will help advance MyOme’s Proactive Health (MPH) Trial—a clinical trial seeking to quantify the cost savings and improved patient outcomes for whole-genome sequencing (WGS) combined with MyOme’s AI-integrated risk models (IRMs)—and help expand MyOme’s suite of proactive health and rare disease diagnostic tests. Neither financial details nor milestones of the investment were disclosed.
The MPH Trial is a planned, large-scale prospective trial that aims to prove enhanced patient outcomes and substantial cost savings resulting from use of whole-genome sequencing (WGS) combined with MyOme’s AI-integrated risk models (IRMs) for common, chronic conditions, cancers, and rare disease. The MPH trial will begin enrollment in 2026.
MyOme believes that use of WGS and IRM would result in early disease detection and intervention and could even prevent or delay the onset of a wide range of chronic and age-related conditions. The company estimates that the US healthcare system could save $200 billion per year.
“MyOme’s approach represents an important evolution in the use of genomics for preventive care,” said Jakob Wedel, chief strategy and corporate development officer of Illumina in a press release. “By combining Illumina’s next-generation sequencing technologies with MyOme’s AI-integrated risk models, we are helping advance science and generate the clinical evidence needed to transform how diseases are detected and managed.”
Proactive Health Suite
The collaboration will also support MyOme’s ability to expand its commercially available products, including a suite of proactive health and rare disease diagnostic tests.
Last month the company launched its Prostate Cancer Integrated Polygenic Risk Score (iPRS) test — a test designed to identify men at elevated genetic risk for prostate cancer, empowering earlier detection and personalized prevention. The Prostate Cancer iPRS test integrates data from approximately 7 million genetic markers with established clinical risk factors to provide individualized 10-year and lifetime risk assessments.
- The Prostate Cancer iPRS test is part of MyOme's growing suite of Proactive Health offerings, which also includes:
- Single-Gene Risk: Detects rare, high-impact variants associated with inherited diseases.
- Medication Response: Identifies genetic variants that influence how individuals metabolize common medications.
- Coronary Artery Disease (CAD) iPRS: Personalized genetic risk assessment for heart attack and coronary events.
- Type 2 Diabetes (T2D) iPRS: Combines genetic and clinical data to refine diabetes risk stratification.
- Breast Cancer iPRS: Provides individualized lifetime breast cancer risk estimates to inform screening and prevention.
By combining Illumina’s leadership in large-scale population health with MyOme’s IRMs, MyOme aims to help patients gain access to more accurate, ancestry-relevant risk assessments for many of the leading causes of death. Illumina’s technology roadmap will accelerate MyOme’s innovation in rare disease testing, further increasing diagnostic yield.
“This collaboration advances science to fundamentally transform healthcare,” said Matt Rabinowitz, PhD, Executive Chairman of MyOme. “MyOme is using whole genome sequencing, cutting-edge bioinformatics and AI analyses to deliver lifelong clinical benefits over diverse situations and phenotypes. These include pharmacogenomic insights, analysis of more than 150 genes with actionable incidental findings and integrated risk models combining polygenic risk scores and other analytes for major cancers, cardiometabolic disease, kidney, liver, cognitive and other diseases. With Illumina’s sequencing technology, we aim to demonstrate how next-generation genomics, integrated with AI-driven risk models, can deliver deeper insights into human biology as well as meaningful economic impact for the U.S.A.”
This financing round is strengthened by continued support from Natera, a global leader in genetic testing and diagnostics that brings deep clinical expertise in cancer detection, women’s health, organ health and hereditary disease. Sequoia Capital, The Duquesne Family Office, and others also participated in the financing.